Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The

endocrine therapy
liver metastasis
paclitaxel
epidermal growth factor receptor
metastasis
  • 0 views
  • 30 Jun, 2022
  • 18 locations
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive human epidermal growth factor receptor 2

cancer
invasive breast cancer
paclitaxel
immunostimulant
breast surgery
  • 18 views
  • 09 May, 2022
  • 2 locations
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing

cancer
immunohistochemistry
epidermal growth factor receptor
human epidermal growth factor
progesterone receptor
  • 107 views
  • 12 Dec, 2021
  • 5 locations
Assessing the Immunogenicity of pING-hHER3FL

protein and will be used in a phase I study as immunotherapeutic agent to target cancers that are known to express the human epidermal growth factor receptor HER3. The human epidermal growth factor

solid tumor
EGFR
metastasis
hormone therapy
metastatic solid tumor
  • 0 views
  • 12 May, 2022
  • 1 location
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

The purpose of this research is to determine the expression of prostate specific membrane antigen (PSMA) in human epidermal growth factor receptor 2 (HER2)-negative, androgen receptor (AR

growth factor
erbb2
HER2
epidermal growth factor
epidermal growth factor receptor
  • 0 views
  • 25 Apr, 2022
  • 1 location
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug. Results from the phase I safety

pertuzumab
growth factor
erbb2
invasive breast cancer
HER2
  • 0 views
  • 11 Aug, 2022
  • 1 location
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024)

Treatment Group) in the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), androgen receptor positive (AR+) with a AR% nuclei staining ≥40% metastatic

  • 0 views
  • 10 Aug, 2022
  • 3 locations
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications

  • 0 views
  • 09 Jul, 2022
  • 1 location
A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Breast cancer is the second most common invasive malignancy and the leading cause of cancer-related mortality in women. Overexpression of human epidermal growth factor receptor 2 (HER2) is

pertuzumab
growth factor
herceptin
erbb2
HER2
  • 0 views
  • 15 Jun, 2022
  • 1 location
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer (InTTercePT)

investigational drug tucatinib to the standard treatment trastuzumab and capecitabine improved both progression-free survival and overall survival in people diagnosed with human epidermal growth factor 2 (HER2

  • 0 views
  • 14 Jun, 2022
  • 19 locations